D228: Cervical Epidural Versus Cevical Facet Injection for Patients With Chronic Cervical Pain

Sponsor
Fayoum University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04594876
Collaborator
(none)
80
2
12.6

Study Details

Study Description

Brief Summary

After approval of the institutional review board and the Ethics Committee of Al Fayoum University number (D228) , and written informed consent from all patientá¹£ Pilot study will be done to confirm this sample size .The patients are classified in two groups group P for cervical epidural and group F for facet injection To compare effectivness of cervical epidural versus cervical facet injection under fluroscopic guidance in patients sufferring from chronic neck pain.

Condition or Disease Intervention/Treatment Phase
  • Other: Flouroscopic guidance cervical epidural versus cervical facet injection
N/A

Detailed Description

After the approval of the institutional review board and the Ethics Committee of Al Fayoum University number (D228) , and written informed consent from all patientá¹£ Pilot study will be done to confirm this sample size .The patients are classified in two groups group P for cervical epidural and group F for facet injection. Patients Inclusion criteria of chronic cervical pain syndromes will be made from their history, symptoms, and imaging diagnosis. Patients will be lying down on the prone position. In group( F) Under the C-arm fluoroscopic guidance targeted zygapophyseal joints will be identified. The mixture of 2 mL of 2% lidocaine with 2 ml of beta methasone (6 mg/ml) will be injected in the joints unilaterally or bilaterally according to complaints of patients. Another group ( P) patients will undergo translaminar or interspinous cervical epidural block (CEBs). The translaminar or interlaminar approach is considered the safest and most effective technique for cervical epidural placement.The patient will be in a prone position. This procedure will be performed with fluoroscopic guidance. The patient will be placed in an optimal flexed cervical spine posture stabilized with enough resistance to prevent movement of the head during the procedure. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance. LA, such as lidocaine, will be used, to mark the intended site of skin entry. As much as 1 mL of lidocaine will be used to infiltrate the skin and subcutaneous tissues. We will insert a 25-gauge, 2-inch needle exactly into the targeted midline. After the LA has been given time to anesthetize the area,we will hold the needle firmly at the hub with the left thumb and index finger. Then the palm of the left hand will be placed firmly against the patient's neck, so that the left hand acts as a unit to stabilize, protect, and control the needle's trajectory and its metered ingress from any unexpected patient activity. The needle will be then advanced with the left hand, which is braced against the neck with the needle hub held tightly between the left thumb and forefinger. We will use the right hand to monitor resistance through a syringe containing air. With constant pressure applied to the plunger of the syringe through light pressure applied by the right thumb, the needle and syringe will be advanced in a slow and deliberate manner. As the bevel passes through the ligament flavum and enters the epidural space, a sudden loss of resistance that we will appreciate also we can appreciate the entrence the epidural space under fluroscopic guidance in condition that not to cross J line (a line appear under flouroscopy imaging facet joint articulation if crossing this line we will puncture the dura).

Needle position within the epidural space will be checked by using fluoroscopic verification and by repeating the loss of resistance maneuver. The cervical epidural space should accept 0.5-1 mL of air or sterile preservative free saline without significant resistance. The force required to depress the plunger should not exceed that which is necessary to overcome the resistance of the needle. Any significant pain or sudden increase in resistance during the injection suggests incorrect needle placement, so the injection will be stopped and we will assess the position of the needle using fluoroscopy. If the needle remains satisfactorily placed and loss of resistance within the epidural space is confirmed without additional patient report of pain, gentle aspiration will be checked to assure that the needle is not positioned in the subarachnoid space or that it's not intravascular. If cerebrospinal fluid (CSF) is aspirated, we will repeat the block attempt at a different interspace. If aspiration of blood occurs, the needle will be tightly rotated and the aspiration test will be repeated. If the aspiration of blood continues, the procedure will be aborted due to the danger of developing an epidural hematoma and possibly neurological compromise. when the needle is correctly placed in the midline of the epidural space, then injection of the mixture of 2 mL of 2% lidocaine with 2 ml of beta methasone (6 mg/ml) will be done .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Group P will receive cervical epidural Group F will receive cervical facet injection Both under fluroscopic guidanceGroup P will receive cervical epidural Group F will receive cervical facet injection Both under fluroscopic guidance
Masking:
Single (Investigator)
Masking Description:
The patients were randomly allocated by a computer-generated table into one of two study groups. The randomization sequence was concealed in opaque sealed envelopes. The envelopes were opened by the study investigators just after recruitments and admission to the operation room. Only assessors and data collectors were blinded to the group's allocations
Primary Purpose:
Supportive Care
Official Title:
Cervical Epidural Versus Cevical Facet Injection for Patients With Chronic Cervical Pain
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Dec 5, 2022
Anticipated Study Completion Date :
Dec 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Flouroscopic guidance Cervical Epidural injection

Group (P) flouroscopic guidance cervical epidural injection

Other: Flouroscopic guidance cervical epidural versus cervical facet injection
The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.

Other: Flouroscopic guidance cervical facet injection

Group (F) Flouroscopic guidance cervical facet injection

Other: Flouroscopic guidance cervical epidural versus cervical facet injection
The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.

Outcome Measures

Primary Outcome Measures

  1. Neck pain disability index preintervention [measured once within 1 day pre intervention]

    The NDI has become a standard instrument for measuring self-rated disability due to neck pain and is used by clinicians and researchers alike. Each of the 10 items is scored from 0 - 5. The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score. Occasionally, a respondent will not complete one question or another. The average of all other items is then added to the completed items. The original report provided scoring intervals for interpretation, as follows: 0 - 4 = no disability 5 - 14 = mild 15 - 24 = moderate 25 - 34 = severe above 34 = complete.

  2. Change in Neck pain disability index post intervention [1 month, 3 month, 6 month,12 month]

    The NDI has become a standard instrument for measuring self-rated disability due to neck pain and is used by clinicians and researchers alike. Each of the 10 items is scored from 0 - 5. The maximum score is therefore 50. The obtained score can be multiplied by 2 to produce a percentage score. Occasionally, a respondent will not complete one question or another. The average of all other items is then added to the completed items. The original report provided scoring intervals for interpretation, as follows: 0 - 4 = no disability 5 - 14 = mild 15 - 24 = moderate 25 - 34 = severe above 34 = complete.

Other Outcome Measures

  1. Total opoid and non steroidal consumption preintervention [measured once 1 day preintervention]

    Pre intervention total dose of opoid and an non steroid consumption

  2. Total opoid and non steroidal consumption post intervention [measured (1 month,3 month,6 month,12 month)"post intervention]

    Total dose intake of opoid and non steroid consumption post intervention

  3. VAS Score [0 hour, 2 hours, 4 hours, 6hours, 12 hours, 18 hours, 24 hours post operative]

    Graded frome 0 no pain to 10 maximum pain

  4. Post operative Nausea & vomiting score [0 hour,2 hours,4 hours,6 hours,12 hours,18 hours,24 hours post operative]

    From grade 0 no nausea or vomiting to grade 4 sever vomitting

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients age between 20 - 70 years old.

  • ASA I and II

  • Cervical pain at least 3 months before procedure

  • Patients have failed pharmacological treatment.

Exclusion Criteria:
  • Systemic infection

  • Skin infection

  • Bleeding tendency and coagulopathy

  • Pregnancy

  • Neurological disorders

  • Any deformaties that disfacilate the procedure

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Fayoum University Hospital

Investigators

  • Principal Investigator: Atef Mahmoud, Fayoum University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Atef Mohamed Sayed mahmoud, Principal investigator, Fayoum University Hospital
ClinicalTrials.gov Identifier:
NCT04594876
Other Study ID Numbers:
  • D228
  • D228
First Posted:
Oct 20, 2020
Last Update Posted:
Aug 17, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Atef Mohamed Sayed mahmoud, Principal investigator, Fayoum University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 17, 2021